TR201502223A2 - Pharmaceutical combinations of dronedarone and dabigatran - Google Patents
Pharmaceutical combinations of dronedarone and dabigatran Download PDFInfo
- Publication number
- TR201502223A2 TR201502223A2 TR2015/02223A TR201502223A TR201502223A2 TR 201502223 A2 TR201502223 A2 TR 201502223A2 TR 2015/02223 A TR2015/02223 A TR 2015/02223A TR 201502223 A TR201502223 A TR 201502223A TR 201502223 A2 TR201502223 A2 TR 201502223A2
- Authority
- TR
- Turkey
- Prior art keywords
- pellets
- pharmaceutical combination
- tablets
- dronedarone
- combination according
- Prior art date
Links
- 229960002084 dronedarone Drugs 0.000 title claims abstract description 28
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960003850 dabigatran Drugs 0.000 title claims abstract description 22
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
- 239000008188 pellet Substances 0.000 claims description 103
- DWKVCQXJYURSIQ-UHFFFAOYSA-N n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;hydron;chloride Chemical compound Cl.C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 DWKVCQXJYURSIQ-UHFFFAOYSA-N 0.000 claims description 46
- 239000003826 tablet Substances 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 39
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 31
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 30
- 229960004951 dabigatran etexilate mesylate Drugs 0.000 claims description 30
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 30
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 29
- 229920001577 copolymer Polymers 0.000 claims description 25
- 229930195725 Mannitol Natural products 0.000 claims description 21
- 239000000594 mannitol Substances 0.000 claims description 21
- 235000010355 mannitol Nutrition 0.000 claims description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 20
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 19
- 239000002702 enteric coating Substances 0.000 claims description 17
- 238000009505 enteric coating Methods 0.000 claims description 17
- 235000000346 sugar Nutrition 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- -1 ampoules Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- CPKOXUVSOOKUDA-UHFFFAOYSA-N 1-bromo-5-fluoro-2-iodo-4-methylbenzene Chemical group CC1=CC(I)=C(Br)C=C1F CPKOXUVSOOKUDA-UHFFFAOYSA-N 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 229960000288 dabigatran etexilate Drugs 0.000 claims description 7
- 229960002919 dronedarone hydrochloride Drugs 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- 239000002270 dispersing agent Substances 0.000 claims description 6
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 230000023555 blood coagulation Effects 0.000 claims description 2
- 238000001246 colloidal dispersion Methods 0.000 claims description 2
- 239000007891 compressed tablet Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 239000007912 modified release tablet Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007935 oral tablet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000008299 semisolid dosage form Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 229920003119 EUDRAGIT E PO Polymers 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 235000012239 silicon dioxide Nutrition 0.000 description 11
- 229960001866 silicon dioxide Drugs 0.000 description 11
- 235000010199 sorbic acid Nutrition 0.000 description 11
- 239000004334 sorbic acid Substances 0.000 description 11
- 229940075582 sorbic acid Drugs 0.000 description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000001361 adipic acid Substances 0.000 description 9
- 235000011037 adipic acid Nutrition 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229920001285 xanthan gum Polymers 0.000 description 9
- 235000010493 xanthan gum Nutrition 0.000 description 9
- 239000000230 xanthan gum Substances 0.000 description 9
- 229940082509 xanthan gum Drugs 0.000 description 9
- 238000005453 pelletization Methods 0.000 description 8
- 239000001384 succinic acid Substances 0.000 description 8
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 7
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 206010003658 Atrial Fibrillation Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 239000003868 thrombin inhibitor Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000004179 indigotine Substances 0.000 description 3
- 235000012738 indigotine Nutrition 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000005563 spheronization Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JMEVHYCNAPFOAB-UHFFFAOYSA-N 2-(3-hydroxy-5-sulfo-1H-indol-2-yl)-3-oxoindole-5-sulfonic acid Chemical compound Oc1c([nH]c2ccc(cc12)S(O)(=O)=O)C1=Nc2ccc(cc2C1=O)S(O)(=O)=O JMEVHYCNAPFOAB-UHFFFAOYSA-N 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000011044 succinic acid Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000093727 Berzelia alopecuroides Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 235000011552 Rhamnus crocea Nutrition 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 1
- 229960000296 desirudin Drugs 0.000 description 1
- 108010073652 desirudin Proteins 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- LSJPSEGDEHIVFE-RJMJUYIDSA-N dioxosilane (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound [Si](=O)=O.OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO LSJPSEGDEHIVFE-RJMJUYIDSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 229960003988 indigo carmine Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960002137 melagatran Drugs 0.000 description 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000016337 monopotassium tartrate Nutrition 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229940066336 pradaxa Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- IZUPJOYPPLEPGM-UHFFFAOYSA-M sodium;hydron;phthalate Chemical compound [Na+].OC(=O)C1=CC=CC=C1C([O-])=O IZUPJOYPPLEPGM-UHFFFAOYSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Mevcut buluş, dronedaron veya farmasotik olarak kabul edilebilir bir tuzu ile birlikte dabigatran veya farmasotik olarak kabul edilebilir bir tuzu veya polimorfu ve en az bir farmasotik olarak kabul edilebilir bir ekspiyan içeren farmasotik bir kombinasyon ile ilgilidir.The present invention relates to a pharmaceutical combination comprising dabigatran or a pharmaceutically acceptable salt or polymorph and at least one pharmaceutically acceptable excipient together with dronedarone or a pharmaceutically acceptable salt thereof.
Description
Tarifname DRONEDARONUN VE DABIGATRANIN FARMASÖTIK KOMBINASYONLARI Bulusun alani Mevcut bulus, dabigatran veya onun farmasötik olarak kabul edilebilir bir tuzu veya farkli bir polimorfu ile birlikte dronedaron veya onun farmasötik olarak kabul edilebilir bir tuzunu ve en az bir tane farmasötik olarak kabul edilebilir yardimci maddeyle içeren farmasötik bir kombinasyonla ilgilidir. specification PHARMACEUTICAL COMBINATIONS OF DRONEDARON AND DABIGATRAN field of invention The present invention includes dabigatran or a pharmaceutically acceptable salt thereof or a different dronedarone or a pharmaceutically acceptable salt thereof, together with its polymorph a pharmaceutical product containing at least one pharmaceutically acceptable excipient It's about the combination.
Bulusun geçmisi Dronedaron, antiaritmik özelliklere sahip Iyodinlenmemis (noniyodinize) bir benzofuran türevidir. Dronedaron, amiodarondan bir iyot kisminin atilmasi ve bir metan sülfonil grubunun eklenmesi bakimindan yapisal olarak farkli bir amiodaron analogudur. Bu modifikasyonlar, tiroit üzerine olan etkileri ve diger advers etkileri azaltir ve dronedaronu daha kisa bir yarilanma ömrü ile daha az Iipofilik hale getirir. Dronedaronun kimyasal ismi N-[2-bütiI-3-[4- Formül l: Dronedaron Formül ll: Dronedaron hidroklorür Dronedaron hidroklorür (formül I'de gösterilen), paroksismal veya persistan atriyal fibrilasyon (AF) öyküsü bulunan, sinüs ritminde seyreden hastalarda AF için hospitalize edilme riskini azaltmak üzere endike gösterilen antiaritmik bir ilaçtir. Yemekle verilmesini takiben, bagirsaklardan iyi derecede emilerek kana geçmektedir. FDA tarafindan 2009 yilinda onaylanmistir ve hali hazirda piyasada MULTAQTM ticari ismi altinda satilmaktadir. Tavsiye edilen doz, sabah ve aksam ögünleri ile günde iki defa 400 mg'lik bir tabletin alinmasidir. history of invention Dronedarone is a non-iodinated benzofuran with antiarrhythmic properties. is derivative. Dronedarone consists of removal of an iodine moiety and a methane sulfonyl group from amiodarone. It is a structurally different analogue of amiodarone in terms of addition. These modifications reduces thyroid and other adverse effects and provides a shorter duration of dronedarone. makes it less Lipophilic with a half-life. Chemical name of dronedarone is N-[2-butyl-3-[4- Formula 1: Dronedarone Formula II: Dronedarone hydrochloride Dronedarone hydrochloride (shown in formula I), paroxysmal or persistent atrial fibrillation Risk of being hospitalized for AF in patients with a history of (AF) and in sinus rhythm. It is an antiarrhythmic drug indicated to reduce Following administration with food, It is well absorbed from the intestines and passes into the blood. by the FDA in 2009. has been approved and is currently marketed under the trade name MULTAQTM. Recommendation The recommended dose is to take one 400 mg tablet twice a day, with morning and evening meals.
Teknigin bilinen durumunda dronedaron ve onun farmasötik olarak kabul edilebilir tuzlari EP basvurusu dronedaron HCl'nin tablet formülasyonlarini bildirmektedir. Ayrica agizdan uygulanan dronedaron formülasyonlarini bildiren bir kaç patent basvurusu da vardiri ancak bu basvurulardan hiç birisi agizda dagilan dronedaron tabletleri içermemektedir. State of the art dronedarone and its pharmaceutically acceptable salts EP reports tablet formulations of dronedarone HCl. Also by word of mouth There are also a few patent applications reporting dronedarone formulations applied, but none of these applications contain dronedarone tablets that disintegrate in the mouth.
Günümüzde yaygin olarak bulunan çok sayida antitrombotik ilaç bulunmaktadir ve trombin enzimini dogrudan inhibe etmek suretiyle antikoagülan (kanin pihtilasmasini geciktirici) etkisini sergileyen bir medikasyon sinifi olan Direkt Trombin Inhibitörleri (DTIler) olarak ta isimlendirilmektedir. DTI'ler hirudin, bivalirudin (IV), lepirudin, desirudin, argatroban (IV), dabigatran, dabigatran eteksilat (oral formülasyonu), melagatran, ksimelagatrani (oral formülasyondur, fakat karaciger komplikasyonlari vardir) ve bunlarin ön ilaçlarini kapsamaktadir. There are many antithrombotic drugs widely available today and thrombin anticoagulant by directly inhibiting the enzyme Also known as Direct Thrombin Inhibitors (DTIs), a class of medications that exert is named. DTIs hirudin, bivalirudin (IV), lepirudin, desirudin, argatroban (IV), dabigatran, dabigatran etexilate (oral formulation), melagatran, ximelagatrani (oral formulation) formulation, but with liver complications) and their prodrugs covers.
Daha önceden WO 98/37075 nolu patent basvurusunda bildirilen dabigatran eteksilat (Formül III), trombinin peptid yapida olmayan, yarismali, geri dönüsümsüz bir antagonistidir. dabigatran etexilate previously reported in patent application WO 98/37075 (Formula III) is a non-peptide, competitive, irreversible antagonist of thrombin.
Vasküler olmayan atriyal fibrilasyon hastalarinda inme ve sistemik emboli riskini azaltmak amaciyla endike gösterilen bir direkt trombin inhibitörüdür. Trombin, faktör Xlll'ü aktive ederek fibrinojeni fibrine, çapraz bagli fibrin monomerlerine dönüstüren ve faktör V ve faktör Vlll'ü aktive ederek te trombin üretimini daha da artiran çok fonksiyonlu bir enzimdir. Ayrica plateletleri aktiflestirir, protein C'yi aktive ederek antikoagülan etkinlik olusturur ve çesitli hücresel prosesleri de baslatir. Reducing the risk of stroke and systemic embolism in patients with nonvascular atrial fibrillation It is a direct thrombin inhibitor indicated for Thrombin activates factor XIII converts fibrinogen to fibrin, cross-linked fibrin monomers, and factor V and factor It is a multifunctional enzyme that further increases the production of thrombin by activating VIII. Moreover It activates platelets, activates protein C, creates anticoagulant activity and has various It also initiates cellular processes.
Formül lll: Dabigatran eteksilat Piyasada halihazirda dabigatran eteksilatin PRADAXA® (75, 110, 150mg'lik) markasi altinda ticari olarak satilan metan sülfonik asit ilave tuzu bulunmaktadir ve dabigatran eteksilat mesilatin (DEM) (Formül lV) pellet kompozisyonu ayrica EP1870100 nolu patent basvurusunda da bildirilmektedir. Bu kompozisyon, organik bir asiti içeren çekirdek bir materyal ve çekirdegi kaplayan bir etken katmanla formüle edilmektedir. Formula III: Dabigatran etexilate Dabigatran etexilatine is currently on the market under the brand name PRADAXA® (75, 110, 150mg). commercially available methane sulfonic acid addition salt and dabigatran etexilate mesylatin (DEM) (Formula IV) pellet composition is also patented EP1870100 reported in the application. This composition is a core compound containing an organic acid. It is formulated with an active layer that covers the material and the core.
Formül IV: Dabigatran eteksilat mesilat Teknik alanda temel olarak yaygin bilgiye göre, antiaritmik ilaçlar, kardiyak aritminin özellikle de atriyal fibrilasyonun tedavisinde antikoagülanlarla kombinasyon halinde yaygin olarak kullanilmaktadir. Ancak teknigin bilinen durumunda dronedaron ve dabigatrani tek dozaj formu içerisinde kombine eden formülasyon bulunmamaktadir. Her birini ayri ayri kullanmak yerine, birden fazla molekülün bir dozaj formu halinde kombine edilmesi hastalarin yasam kalitesini ve hasta kompliyansini artirmaktadir. Bu sebeple, teknikte dronedaron ve bir antikoagülan olarak ta dabigatran eteksilati içeren uygun bir farmasötik dozaj Diger taraftan, iki veya fazla molekülü tek dozaj formu içerisinde kombine edilmesi dissolüsyon, geçimlilik ve stabilite problemleri gibi çok sayida soruna da yol açabilir. Her bir ilaç molekülü farkli kimyasal özelliklere ve dissolüsyon özelliklerine sahiptir. Uygulamadan sonra farkli emilim ve çözünme yolaklarini izleyebilirler. Bu nedenle ilaç moleküllerinin, istenen dissolüsyon özelliklerine sahip tek dozaj formu içerisinde kombine edilmesi kolay degildir. Kombine edilen ilaçlar ayrica birbiri ile veya kullanilan diger yardimci maddeler ile reaksiyona girebilir ve istenmeyen stabilite problemlerine yol açabilir. Bunlar haricinde ayni terapötik alanda kullanilan ve hatta ayni endikasyonu tedavi etmek için kullanilan ilaçlarin, asgari e terapötik etkilerin meydana gelmesi ihtimaliyle her zaman için ayni ve etkili dozaj formlari içerisinde kombine edilemedigi iyi bilinmektedir. Formula IV: Dabigatran etexilate mesylate According to widely known technical art, antiarrhythmic drugs are especially effective for cardiac arrhythmias. It is widely used in combination with anticoagulants in the treatment of atrial fibrillation in is used. However, in the state of the art, dronedarone and dabigatrani are single dosage There is no combination formulation in its form. Using each separately Rather, combining more than one molecule into a dosage form can lead to patients' survival. improves quality and patient compliance. For this reason, dronedarone and a A suitable pharmaceutical dosage form containing dabigatran etexilate as an anticoagulant On the other hand, combining two or more molecules in a single dosage form Dissolution can also cause many problems such as compatibility and stability problems. Each drug molecule has different chemical properties and dissolution properties. From the app then they can follow different absorption and dissolution pathways. Therefore, drug molecules easy to combine in a single dosage form with desired dissolution properties is not. Combined drugs can also be combined with each other or with other excipients used. may react and cause undesirable stability problems. Apart from these, the same drugs used in the therapeutic field or even used to treat the same indication, always the same and effective dosage with minimal probability of therapeutic effects to occur It is well known that it cannot be combined in its forms.
Mevcut bulusta, antiaritmik bir ilaç olarak dronedaron ve antikoagülan bir ilaç olarak da dabigatran tek dozaj formu içerisinde kombine edilmektedir ve kardiyovasküler hastaliklarin etkili ve güvenilir tedavisine ulasilmaktadir. In the present invention, dronedarone as an antiarrhythmic drug and also as an anticoagulant drug dabigatran is combined in a single dosage form and is used to treat cardiovascular diseases. effective and reliable treatment is reached.
Bulusun ayrintili açiklamasi Mevcut bulus, dabigatran veya onun farmasötik olarak kabul edilebilir bir tuzu veya farkli bir polimorfu ile birlikte dronedaron veya onun farmasötik olarak kabul edilebilir bir tuzunu ve en az bir tane farmasötik olarak kabul edilebilir yardimci maddele içeren farmasötik bir kombinasyonla ilgilidir. Detailed description of the invention The present invention includes dabigatran or a pharmaceutically acceptable salt thereof or a different dronedarone or a pharmaceutically acceptable salt thereof, together with its polymorph a pharmaceutical product containing at least one pharmaceutically acceptable excipient It's about the combination.
Bir düzenlemeye göre, mevcut bulusta kullanilan dronedaron veya farmasötik olarak kabul edilebilir bir tuzu, dronedaron hidroklorürdür. According to one embodiment, dronedarone used in the present invention or considered pharmaceutical An acceptable salt of it is dronedarone hydrochloride.
Bir düzenlemeye göre, dronedaron hidroklorür (HCI), toplam formülasyonun agirlikça %50 bir miktardadir. arasi ve daha tercihen de 400 ila 800 mg arasi bir miktarda bulunmaktadir. According to one embodiment, dronedarone hydrochloride (HCI) is 50% by weight of the total formulation. is an amount. and more preferably between 400 and 800 mg.
Bir düzenlemeye göre dabigatran veya farmasötik olarak kabul edilebilir bir tuzu veya farkli bir polimorfu, dabigatranin eteksilat veya eteksilat mesilat tuzudur. According to one embodiment, dabigatran or a pharmaceutically acceptable salt or a different a polymorph is the etexilate or mesylate salt of dabigatranin.
Bir düzenlemeye göre dabigatran veya a farmasötik olarak kabul edilebilir bir tuzu, dabigatran eteksilat mesilattir. According to one embodiment, dabigatran or a pharmaceutically acceptable salt thereof, dabigatran etexilate is mesylate.
Bir düzenlemeye göre dabigatran eteksilat mesilat, toplam formülasyonun agirlikça %10 ila miktardadir. mg arasi ve daha tercihen de 50 ila 250 mg arasi bir miktarda bulunmaktadir. According to one embodiment, dabigatran etexilate mesylate comprises from 10% to 10% by weight of the total formulation. amount. mg, and more preferably 50 to 250 mg.
Mevcut bulusta, dronedaron HCI kombinasyon halinde antikoagülan bir ajan olan dabigatran eteksilat mesilat ile birlikte, hastalarda kardiyak aritminin ve kan pihtilasmasinin tedavisinde ve ciddi ve yasami tehdit eden yan etkilerin önlenmesi amaciyla kullanilmaktadir. In the present invention, dronedarone HCl is used in combination with dabigatran, an anticoagulant agent. in combination with etexilate mesylate for the treatment of cardiac arrhythmia and blood coagulation in patients and to prevent serious and life-threatening side effects.
Bir düzenlemede, her bir ilaç molekülü için güvenilir ve etkili dissolüsyon profillerine sahip stabil bir farmasötik kombinasyon saglayan, dabigatran eteksilat mesilat ile birlikte dronedaron HCI içeren farmasötik bir dozaj gelistirilmistir. In one embodiment, they have reliable and effective dissolution profiles for each drug molecule. in combination with dabigatran etexilate mesylate, providing a stable pharmaceutical combination A pharmaceutical dosage containing dronedarone HCl has been developed.
Bir düzenlemeye göre, mevcut bulusta kullanilan oranlar, tedavi edici ve hem dronedaron HCl hem de dabigatran eteksilat mesilat için stabilite saglayan gerekli miktardaki etkili dozlari saglamaktadir. According to one embodiment, the ratios used in the present invention are both therapeutic and dronedarone. Effective doses of HCl and dabigatran etexilate mesylate in the required amount to provide stability it provides.
Bu düzenlemede dronedaron HCl'nin dabigatran eteksilat mesilat'a olan 0.10- 50.0(a/a), formülasyonun bir yandan kombinasyonun stabilitesini sürdürürken bir yandan da hastalar tarafindan kolaylikla yutulabilecek arzu edilen agirlikta bir dozaj formuna kolaylikla islenmesine yardimci oldugu bulunmustur. In this embodiment, the ratio of dronedarone HCl to dabigatran etexilate mesylate is 0.10-50.0(w/w), formulation while maintaining the stability of the combination, while patients readily into a dosage form of desired weight that can be easily swallowed by It has been found to help with processing.
Bir düzenlemede, mevcut bulustaki bir dozaj formunda formüle edilen farmasötik kombinasyon, hem dronedaron HCI hem de dabigatran eteksilat mesilat için istenen dissolüsyon profilini saglamaktadir. In one embodiment, the pharmaceutical formulated in a dosage form of the present invention The combination is desirable for both dronedarone HCl and dabigatran etexilate mesylate. provides the dissolution profile.
Mevcut bulusun bir düzenlemesine göre, farmasötik kombinasyon kati, sivi veya yari kati dozaj formundadir. According to one embodiment of the present invention, the pharmaceutical combination is solid, liquid or semisolid. in dosage form.
Bu düzenlemede, bu farmasötik kombinasyonlar agizdan, parenteral, intranazal, dilalti, transdermal, transmukozal, oftalmik, intravenöz, pulmoner, intramusküler veya rektal uygulama yollari ile uygulanmaktadir ve tercihen de agizdan uygulanmaktadir. In this embodiment, these pharmaceutical combinations are oral, parenteral, intranasal, sublingual, transdermal, transmucosal, ophthalmic, intravenous, pulmonary, intramuscular or rectal It is administered by administration routes and preferably orally.
Bir düzenlemeye göre, farmasötik kombinasyonlar sikistirilmis tabletler, kapli veya kaplanmamis tabletler içeren tabletler, kapsüller, çok katmanli tabletler, agiz içi tabletler, dil alti tabletler, tablet içinde tabletler, in-lay tabletler, efervesan kombinasyonlar, efervesan tabletler, hemen salimli tabletler, modifiye salimli tabletler, ODT (agizda dagilan tablet), film- kapli tabletler, agizda dagilan tabletler, midede dagilan tabletler, haplar, sert veya yumusak jelatin kapsüller, tozlar, mini tabletler, pelletler, kapli boncuk sistemleri, granüller, mikrosferler, iyon degistirici reçine sistemleri, steril solüsyonlar veya süspansiyonlar, steril oküler solüsyonlar, aerosoller, spreyler, damlalar, ampuller,suppozituarlar, oküler sistemler, parenteral sistemler, kremler, jeller, merhemler, drajeler, kaseler; filmler, agizdan uygulanabilen filmler, agizdan uygulanabilen filmler, solüsyonlar, solidler; eliksirler, tentürler, süspansiyonlar, suruplar, kolloidal dispersiyonlar, dispersiyonlar ve emülsiyonlar formundadir Bir düzenlemede, bahsedilen farmasötik kombinasyon tablet veya kapsül veya çok katmanli tablet formunda formüle edilmektedir. According to one embodiment, pharmaceutical combinations are compressed tablets, coated or tablets containing uncoated tablets, capsules, multilayer tablets, oral tablets, lingual six tablets, tablets in tablets, in-lay tablets, effervescent combinations, effervescent tablets, immediate-release tablets, modified-release tablets, ODT (mouth dispersal tablet), film- Coated tablets, orodispersible tablets, gastro-dispersal tablets, pills, hard or soft gelatin capsules, powders, mini tablets, pellets, coated bead systems, granules, microspheres, ion exchange resin systems, sterile solutions or suspensions, sterile ocular solutions, aerosols, sprays, drops, ampoules, suppositories, ocular systems, parenteral systems, creams, gels, ointments, dragees, bowls; movies by mouth applicable films, orally applicable films, solutions, solids; elixirs, tinctures, in the form of suspensions, syrups, colloidal dispersions, dispersions and emulsions In one embodiment, said pharmaceutical combination is a tablet or capsule or a multilayer It is formulated in tablet form.
Bir düzenlemede, bahsedilen farmasötik kombinasyon dronedaron HCI pelletleri ve dabigatran eteksilat mesilat pelletleri içeren tablet veya kapsül veya çok katmanli tablet Dronedaron, bagirsaklardan iyi emilen bir ilaç molekülüdür ve dabigatran ise mideden iyi emilen bir ilaç molekülüdür. Mevcut bulusun bu kombinasyonunda midede çözünmeyen bagirsaklarda çözünen dronedaron HCI pelletler ve midedede çözünen dabigatran eteksilat mesilat pelletler elde edilmektedir. In one embodiment, said pharmaceutical combination is dronedarone HCl pellets and tablet or capsule or multilayer tablet containing dabigatran etexilate mesylate pellets Dronedarone is a drug molecule that is well absorbed from the intestines, and dabigatran is well absorbed from the stomach. It is an absorbed drug molecule. In this combination of the present invention, the insoluble gut soluble dronedarone HCl pellets and stomach soluble dabigatran etexilate mesylate pellets are obtained.
Bir düzenlemedei bahsedilen farmasötik kombinasyon, enterik bir kaplama içeren dronedaron HCl pelletler içermektedir. In one embodiment, said pharmaceutical combination contains an enteric coating. Contains dronedarone HCl pellets.
Bir düzenlemeye göre, mevcut bulusta kullanilan enterik kaplama dronedaron HCI'nin mideden emilmesini degil de, bagirsaklardan emilmesini saglamaktadir. According to one embodiment, the enteric coating dronedarone HCl used in the present invention is It ensures that it is not absorbed from the stomach, but from the intestines.
Mevcut bulus, dronedaron HCI katmanini kaplayan ve dabigatran eteksilat mesilat ile dronedaron HCI katmanlarini birbirinden ayiran enterik bir kaplama içeren farmasötik bir kombinasyon saglamaktadir. Enterik kaplama, dronedaron HCl'nin midede stabil kalmasini saglar ve ayni zamanda enterik kaplama sayesinde dabigatran eteksilat mesilat ve dronedaron HCi molekülleri arasindaki etkilesim de engellenmis olur. Baska bir önemli sebep te farkli salim profillerine sahip ilaç moleküllerinin enterik kaplama ile ayni dozaj formu içerisinde verilebilmesidir. Bu sebeple dabigatran eteksilat mesilat ve dronedaron HCI molekülleri etkilesime girmeyen bir tarzda formüle edilmektedir ve ayni zamanda bu moleküllerin kendi formlarinda stabil kalmalarini da saglar. Ayrica kardiyovasküler hastaliklarin güvenilir ve etkili bir tedavisi yönünden de her bir ilaç molekülünün arzu edilen salim profillerine de ulasilmis olur. The present invention covers the dronedarone HCl layer with dabigatran etexilate mesylate. dronedarone is a pharmaceutical product containing an enteric coating that separates the HCl layers. provides combination. Enteric coating allows dronedarone HCl to remain stable in the stomach. and at the same time, thanks to the enteric coating, dabigatran etexilate mesylate and The interaction between dronedarone HCi molecules is also inhibited. Another important reason The same dosage form with enteric coating of drug molecules with different release profiles can be given in. For this reason, dabigatran etexilate mesylate and dronedarone HCl molecules are formulated in a non-interacting manner and at the same time this It also ensures that the molecules remain stable in their own form. Also cardiovascular In terms of a reliable and effective treatment of diseases, each drug molecule is desired. release profiles can also be reached.
Mevcut bulusun bu düzenlemesinde, dronedaron HCI pelletler selüloz asetat fitalat, metakrilik asit kopolimerleri (Eudragit L tipleri (metakrilik asit, etil akrilat kopolimerleri), Eudragit RL ve R8 tipleri (etil akrilat, metil metakrilat ve amonyum metakrilat kopolimeri), Eudragit-S tipleri (Metakrilik asit, metil metakrilat kopolimeri)), hidroksipropil metilselüloz fitalat (HPMCP), hidroksipropil metilselüloz asetat süksinat, polivinil asetat fitalat ve metakrilik asit ko-polimeri tip C'yi içeren gruptan seçilen enterik bir kaplama içermektedir. In this embodiment of the present invention, dronedarone HCl pellets are made from cellulose acetate phthalate, methacrylic acid copolymers (Eudragit L types (methacrylic acid, ethyl acrylate copolymers), Eudragit RL and R8 types (ethyl acrylate, methyl methacrylate and ammonium methacrylate copolymer), Eudragit-S types (Methacrylic acid, methyl methacrylate copolymer)), hydroxypropyl methylcellulose phthalate (HPMCP), co-polymer of hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate and methacrylic acid containing an enteric coating selected from the group consisting of type C.
Mevcut bulusun bu düzenlemesinde, bahsedilen farmasötik kombinasyon ayri pelletler veya çift katmanli pelletler veya çok katmanli pelletler halindeki dabigatran eteksilat mesilat pelletleri ve dronedaron HCI pelletleri içeren tablet veya kapsül veya çok katmanli tablet formundadir. In this embodiment of the present invention, said pharmaceutical combination is used as separate pellets or dabigatran etexilate mesylate in bilayer pellets or multilayer pellets tablet or capsule or multilayer tablet containing pellets and dronedarone HCl pellets is in the form.
Mevcut bulusun bir düzenlemesinde, bahsedilen dronedaron HCl pelletler farmasötik olarak kabul edilebilir yardimci maddeler olarak mannitol veya prejelatinize nisasta veya karbomer veya kroskarmelloz sodyum veya polivinilpirolidon (PVP) veya polivinil alkol veya seker pellet veya mikrokristalize selüloz (MCC) pellet veya hidroksipropil selüloz veya renklendirici ajan veya bunlarin karisimlarini içermektedir. In one embodiment of the present invention, said dronedarone HCl pellets are pharmaceutically mannitol or pregelatinized starch or carbomer as acceptable excipients or croscarmellose sodium or polyvinylpyrrolidone (PVP) or polyvinyl alcohol or sugar pellets or microcrystalline cellulose (MCC) pellet or hydroxypropyl cellulose or coloring agent or mixtures thereof.
Mevcut bulusun bu düzenlemesinde, bahsedilen dabigatran eteksilat mesilat pelletler farmasötik olarak kabul edilebilir yardimci maddeler olarak polivinil alkol (PVA) veya izopropil alkol (IPA) veya sodyum aljinat veya metakrilik asit-etil akrilat kopolimeri (Eudragit EPO) veya propilen glikol veya laktoz monohidrat veya mannitol veya seker pellet veya polivinilpirolidon (PVP) veya bunlarin karisimlarini içermektedir. In this embodiment of the present invention, said dabigatran etexilate mesylate pellets polyvinyl alcohol (PVA) or isopropyl as pharmaceutically acceptable excipients alcohol (IPA) or sodium alginate or methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or propylene glycol or lactose monohydrate or mannitol or sugar pellets or polyvinylpyrrolidone (PVP) or mixtures thereof.
Bu nedenle yukarida bahsedilen sorunlara göre yardimci maddelerin seçimi önemlidir. Bu düzenlemeye göre, bir veya daha fazla sayida farmasötik olarak kabul edilebilir yardimci madde tamponlayici ajanlar, stabilizörler, baglayicilar, seyrelticiler, disperze edici ajanlar, kayganlastiricilar, glidanlar, dagiticilar, plastiklestiriciler, koruyucular, tatlandiricilar, aroma katici ajanlar, renklendirici ajanlar veya bunlarin karisimlarini içeren gruptan seçilmektedir. For this reason, the selection of excipients according to the problems mentioned above is important. This one or more pharmaceutically acceptable excipients, according to regulation substance buffering agents, stabilizers, binders, diluents, dispersing agents, lubricants, glidants, dispersants, plasticizers, preservatives, sweeteners, flavorings are selected from the group consisting of additives, coloring agents or mixtures thereof.
Uygun tamponlayici ajanlar alkali metal sitrat, sitrik asit/sodyum sitrat, tartarik asit, fumarik asit, sorbik asit, sitrik asit, süksinikasit, adipik asit, askorbik asit, sorbik asit, glutarik asit, potasyum hidrojen tartarat, sodyum hidrojen tartarat, potasyum hidrojen fitalat, sodyum hidrojen fitalat, potasyum dihidrojen fosfat, sodyum dihidrojen fosfat, disodyum hidrojen fosfat, hidroklorik asit/sodyum hidroksit veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir ve tercihen sitrik asit, fumarik asit, askorbik asit, sodyum dihidrojen fosfat veya bunlarin karisimlaridir. Suitable buffering agents are alkali metal citrate, citric acid/sodium citrate, tartaric acid, fumaric acid, sorbic acid, citric acid, succinic acid, adipic acid, ascorbic acid, sorbic acid, glutaric acid, potassium hydrogen tartrate, sodium hydrogen tartrate, potassium hydrogen phthalate, sodium hydrogen phthalate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen may contain phosphate, hydrochloric acid/sodium hydroxide or mixtures thereof, but not limited and preferably citric acid, fumaric acid, ascorbic acid, sodium dihydrogen phosphate or are mixtures of these.
Uygun stabilizörler sitrik asit, fumarik asit, tartarik asit, sodyum sitrat, sodyum benzoat, sodyum dihidrojen fosfat, kalsiyum karbonat, magnezyum karbonat, arjinin, lizin, meglamin, tokoferol, bütilhidroksianizol (BHA), bütilhidroksianitoluen (BHT), askorbik asit, gallik asit esterleri veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir ve tercihen de sitrik asit, fumarik asit, arjinin veya bunlarin karisimlaridir. Suitable stabilizers are citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglamine, tocopherol, butylhydroxyanisole (BHA), butylhydroxyanitoluene (BHT), ascorbic acid, gallic acid esters or mixtures thereof, but not limited to, and preferably citric acid, fumaric acid, arginine or mixtures thereof.
Uygun baglayicilar ksantan zamki, prejelatinize nisasta, polivinilpirolidon, polietilen glikol, polivinil alkol, nisasta, glikoz, glikoz surubu, dogal zamklar, sükroz, sodyum aljinat, hidroksipropil metil selüloz, hidroksipropil selüloz, karboksi metil selüloz, metil selüloz gibi selüloz türevleri, jelatin, karragenan, guar zamki, karbomer, polimetakrilatlar, metakrilat polimerleri, kollajenler, jelatin gibi proteinler, agar, aljinat, aiginik asit, hiyaluronik asit, pektin, polisakkaritler, karbomer, polokzamer, poliakrilamid, alüminyum hidroksit, laponit, bentonit, polioksietilen-alkil eter, polidekstroz, polietilen oksit veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable binders are xanthan gum, pregelatinized starch, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose cellulose derivatives, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, collagens, proteins such as gelatin, agar, alginate, aiginic acid, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, laponite, bentonite, may contain polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof, but not angry with them.
Uygun seyrelticiler mannitol, laktoz, mikrokristalize selüloz, spreyle kurutulmus mannitol, nisasta, dekstroz, sükroz, fruktoz, maltoz, sorbitol, ksilitol, inozitol, kaolin, inorganik tuzlar, kalsiyum tuzlari, polisakkaritler, dikalsiyum fosfat, sodyum klorür, dekstratlar, laktilol, maltodekstrin, sükroz-maltodekstrin karisimi, trehaloz, sodyum karbonat, sodyum bikarbonat, kalsiyum karbonat veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable diluents are mannitol, lactose, microcrystalline cellulose, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactilol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, may contain, but is not limited to, calcium carbonate or mixtures thereof.
Uygun disperze edici ajanlar kalsiyum silikat, magnezyum alüminyum silikat veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable dispersing agents are calcium silicate, magnesium aluminum silicate or their may include, but is not limited to.
Uygun kayganlastiricilar magnezyum stearat, kalsiyum stearat, çinko stearat, talk, mumlar, borik asit, hidrojenize bitkisel yag, sodyum klorat, magnezyum lauril sülfat, sodyum oleat, sodyum asetat, sodyum benzoat, polietilen glikol, stearik asit, yag asidi, fumarik asit, gliseril palmito sülfat, sodyum stearil fumarat, sodyum lauril sülfat veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable lubricants are magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulfate, sodium stearyl fumarate, sodium lauryl sulfate or mixtures thereof. may include, but is not limited to.
Uygun glidanlar talk, alüminyum silikat, kolloidal silika, nisasta veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable glidants include talc, aluminum silicate, colloidal silica, starch or mixtures thereof. may include, but is not limited to.
Uygun dagiticilar prejelatinize nisasta, çapraz bagli polivinil pirolidon (krospovidon), povidon, çapraz bagli karboksimetil selüloz (kroskarmelloz sodyum), düsük-susbtitüe hidroksipropil selüloz, sodyum karboksimetil selüloz, kalsiyum karboksimetil selüloz, karboksimetil selüloz, dokuzat sodyum, guar zamki, düsük-susbtitüe hidroksipropil selüloz, poliakrilin potasyum, sodyum aljinat, misir nisastasi, sodyum nisasta glikollat, aljinik asit, aljinatlar, iyon-degistirici reçineler, magnezyum alüminyum silika, sodyum dodesil sülfat, polokzamer, sodyum glisin karbonat, sodyum Iauril sülfat veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable dispersants are pregelatinized starch, cross-linked polyvinyl pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, nineate sodium, guar gum, low-substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycollate, alginic acid, alginates, ion-exchanger resins, magnesium aluminum silica, sodium dodecyl sulfate, poloxamer, sodium glycine may contain, but not limited to, carbonate, sodium lauryl sulfate, or mixtures thereof. is not.
Uygun plastiklestiriciler farkli moleküler agirliklarda polietilen glikoller, propilen glikol, gliserin, trietil sitrat (TEC), triasetin, dietil fitalat (DEP), dibütil fitalat (DBP), tribütil sitrat (TBC), kastor yagi, dibütil sebasat (DBS), diasetillenmis monogliseridler veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable plasticizers are polyethylene glycols of different molecular weights, propylene glycol, glycerine, triethyl citrate (TEC), triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP), tributyl citrate (TBC), castor oil, dibutyl sebacate (DBS), diacetylated monoglycerides or mixtures thereof. may include, but is not limited to.
Uygun koruyucular metil paraben, propil paraben ve onlarin tuzlari (sodyum, potasyum gibi), sodyum benzoat, sitrik asit, benzoik asit, bütillenmis hidroksitoluen, borik asit, sorbik asit, benzil alkol, benzalkonyum klorür, parahidroksibenzoik asitler veya bütillenmis hidroksianizol ve benzerlerini veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable preservatives are methyl paraben, propyl paraben and their salts (such as sodium, potassium), sodium benzoate, citric acid, benzoic acid, butylated hydroxytoluene, boric acid, sorbic acid, benzyl alcohol, benzalkonium chloride, parahydroxybenzoic acids or butylated hydroxyanisole and the like, or mixtures thereof, but are not limited to.
Uygun tatlandiricilar aspartam, potasyum asesülfam, sodyum sakkarinat, neohesperidin dihidrokalkon, sükraloz, sakkarin, sükroz, glikoz, laktoz, früktoz gibi sekerler veya mannitol, sorbitol, ksiIitol, eritritol gibi seker alkollerini veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable sweeteners are aspartame, potassium acesulfame, sodium saccharinate, neohesperidin sugars such as dihydrochalcone, sucralose, saccharine, sucrose, glucose, lactose, fructose or mannitol, may contain sugar alcohols such as sorbitol, xylitol, erythritol or mixtures thereof, but not angry with them.
Uygun aroma katici ajanlar mentol, nane, tarçin, çikolata, vanilya veya visne, portakal, çilek, üzüm, siyah frenküzümü, ahududu, muz, kirmizi meyveler, yabani meyveler gibi meyve esanslari veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable flavoring agents are menthol, mint, cinnamon, chocolate, vanilla or cherry, orange, strawberry, fruit such as grapes, black currant, raspberry, banana, red berries, wild berries may include, but is not limited to, essences or mixtures thereof.
Uygun renklendirici ajanlar ferrik oksit, titanyum dioksit, Food, Drug & Cosmetic (FD&C) boyalari (FD&C mavisi, FD&C yesili, FD&C kirmizisi, FD&C sarisi, FD&C koyu kirmizisi gibi), poncau, indigo Drug & Cosmetic (D&C) mavisi, indigotin FD&C mavisi, karmoizin indigotin (indigo Karmin); demir oksitler (kirmizi, sari, siyah demir oksit gibi), kinolin sarisi, ates kirmizisi, karmin, karmoizin, gün batimi sarisi boyalarini veya bunlarin karisimlarini içerebilir, ancak bunlarla sinirli degildir. Suitable coloring agents are ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C dark red etc.), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoizine indigotine (indigo Carmine); iron oxides (such as red, yellow, black iron oxide), quinoline yellow, paints fire red, carmine, carmoizine, sunset yellow or their mixtures. may include, but is not limited to.
Bilesenler Miktar (%) Dronedaron HCl pelletler ' dronedaron HCl 5.00 - 98.00 mannitol 5.00 - 90.00 prejelatinize nisasta 5.00 - 90.00 Enterik kaplama selüloz asetat fitalat 0.10 - 30.00 Dabigatran eteksilat mesilat pelletler dabigatran eteksilat mesilat 1.00 - 85.00 adipik asit veya sorbik asit 5.00 - 95.00 veya süksinik asit veya glutarik asit polivinil alkol (PVA) veya 0.05 - 20.00 izopropil alkol (IPA) sodyum aljinat 0.05 - 20.00 metakrilik asit-Etil akrilat 0.05 - 40.00 kopolimeri (Eudragit EPO) veya PVA xanthan gum 0.05 - 5.00 silikon dioksit 0.10 -1.00 magnezyum stearat 0.10 - 3.00 Dronedaron HCI pelletlerin üretim prosesi: Dronedaron HCI, mannitol ve prejelatinize nisasta önce hep bir arada karistirilir, sonrasinda da polivinil pirolidon solüsyonunun püskürtülmesiyle islak bir kütle olusturulur. Ekstrüzyon/sferonizasyon pelletleme teknigi ile bu islak kütleden pelletler üretilmektedir. Enterik kaplama olarak selüloz asetat fitalat eklenerek bir solüsyon/dispersiyon hazirlanir ve dronedaron HCl pelletler bu karisimin püskürtülmesi ile kaplanir. Components Quantity (%) Dronedarone HCl pellets' dronedarone HCl 5.00 - 98.00 mannitol 5.00 - 90.00 pregelatinized starch 5.00 - 90.00 enteric coating cellulose acetate phthalate 0.10 - 30.00 Dabigatran etexilate mesylate pellets dabigatran etexilate mesylate 1.00 - 85.00 adipic acid or sorbic acid 5.00 - 95.00 or succinic acid or glutaric acid polyvinyl alcohol (PVA) or 0.05 - 20.00 isopropyl alcohol (IPA) sodium alginate 0.05 - 20.00 methacrylic acid-Ethyl acrylate 0.05 - 40.00 copolymer (Eudragit EPO) or PVA xanthan gum 0.05 - 5.00 silicon dioxide 0.10 -1.00 magnesium stearate 0.10 - 3.00 Production process of Dronedarone HCl pellets: Dronedarone HCl, mannitol and pregelatinized The starch is first mixed together, and then the polyvinyl pyrrolidone solution is mixed. A wet mass is formed by spraying. With the extrusion/spheronization pelletizing technique, this Pellets are produced from the wet mass. By adding cellulose acetate phthalate as enteric coating A solution/dispersion is prepared and dronedarone HCl pellets are made by spraying this mixture. is covered.
Dabigatranla kaplianmis organik asit pelletlerin üretim prosesi: Adipik asit veya sorbik asit veya süksinik asit veya glutarik asit ve ksantan zamki birarada karistirilir. Bu karisimin üzerine alkollü polivinil alkol (PVA) veya lPA (izopropil alkol) solüsyonu püskürtülür ve akiskan yatakli peletleme teknigi ile pelletler üretilir. Pelletler, akiskan yatakta sodyum aljinat ile kaplanir ve böylece pelletler üretilmis olur. DEM (dabigatran etaksilat mesilat) alkollü metakrilik asit-etil akrilat kopolimeri (Eudragit EPO) veya polivinil alkol (PVA) solüsyonu içerisinde çözdürülür. Bu solüsyoni akiskan yatakli pelletleme teknigi ile asit pelletler üzerine püskürtülür, böylelikle çok katmanli pelletler üretilmis olur. Production process of organic acid pellets coated with dabigatran: Adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum mixed together. on this mix alcoholic solution of polyvinyl alcohol (PVA) or IPA (isopropyl alcohol) sprayed and fluidized bed Pellets are produced by the pelleting technique. The pellets are coated with sodium alginate in a fluidized bed and Thus, pellets are produced. DEM (dabigatran ethoxylate mesylate) alcohol methacrylic acid-ethyl It is dissolved in a solution of acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA). This The solution is sprayed on the acid pellets with the fluidized bed pelletizing technique, so that it is very layered pellets are produced.
DEM ve dronedaron HCl pelletler önce silikon dioksit ile sonra da magnezyum stearat ile karistirilir. Son olarak pelletler, tabletler halinde basilir veya kapsüllerin içerisinde doldurulur. DEM and dronedarone HCl pellets were mixed first with silicon dioxide and then with magnesium stearate. is mixed. Finally, the pellets are compressed into tablets or filled into capsules.
Bilesenler Miktar (%) Dronedaron HCI pelletler dronedaron HCI 5.00 - 98.00 mannitol 5.00 - 90.00 prejelatinize nisasta 5.00 - 90.00 karbomer 0.10 - 30.00 Enterik kaplama ve amonyum metakrilat kopolimeri Dabigatran eteksilat mesilat pelletler dabigatran eteksilat mesilat 1.00 - 85.00 adipik asit veya sorbik asit 5.00 - 95.00 veya süksinik asit veya glutarik asit metakrilik asit-Etil akrilat 0.05 - 40.00 kopolimeri (Eudragit EPO) veya PVA mannitol 5.0 - 90.00 ksantan zamki 0.05 - 5.00 magnezyum stearat 0.10 - 3.00 silikon dioksit 0.10 -1.00 Dronedaron HCI pelletlerin üretim prosesi: Dronedaron HCI, mannitol ve prejelatinize nisasta önce hep bir arada karistirilir, sonrasinda da karbomer solüsyonunun püskürtülmesiyle islak bir kütle olusturulur. Ekstrüzyon/sferonizasyon pelletleme teknigi ile bu islak kütleden pelletler üretilmektedir. Enterik kaplama olarak etil akrilat, metil metakrilat ve amonyum metakrilat kopolimeri eklenerek bir solüsyon/dispersiyon hazirlanir ve dronedaron HCI pelletler akiskan yatakta bu karisimin püskürtülmesi ile kaplanir. Components Quantity (%) Dronedarone HCl pellets dronedarone HCI 5.00 - 98.00 mannitol 5.00 - 90.00 pregelatinized starch 5.00 - 90.00 carbomer 0.10 - 30.00 enteric coating and ammonium methacrylate copolymer Dabigatran etexilate mesylate pellets dabigatran etexilate mesylate 1.00 - 85.00 adipic acid or sorbic acid 5.00 - 95.00 or succinic acid or glutaric acid methacrylic acid-Ethyl acrylate 0.05 - 40.00 copolymer (Eudragit EPO) or PVA mannitol 5.0 - 90.00 xanthan gum 0.05 - 5.00 magnesium stearate 0.10 - 3.00 silicon dioxide 0.10 -1.00 Production process of Dronedarone HCl pellets: Dronedarone HCl, mannitol and pregelatinized starch It is first mixed all together, then wet by spraying the carbomer solution. mass is created. Pellets from this wet mass by extrusion/spheronization pelletizing technique is produced. Ethyl acrylate, methyl methacrylate and ammonium methacrylate as enteric coating A solution/dispersion is prepared by adding the copolymer and dronedarone HCl pellets are fluidized. The bed is covered by spraying this mixture.
Dabigatran pelletlerin üretim prosesi: DEM ve mannitol birarada karistirilir. Bu karisimin üzerine alkolik metakrilik asit-etil akrilat kopolimeri (Eudragit EPO) veya polivinil alkol (PVA) solüsyonu püskürtülür ve akiskan yatakli pelletleme teknigi ile pelletler üretilir. Adipik asit veya sorbik asit veya süksinik asit veya glutarik asit ve ksantan zamki ile bir solüsyon hazirlanir. Bu solüsyon, akiskan yatakli pelletleme teknigi ile asit pelletler üzerine püskürtülür, böylelikle çok katmanli pelletler üretilmis olur. Production process of dabigatran pellets: DEM and mannitol are mixed together. This is my wife alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution is sprayed and pellets are produced by fluidized bed pelletizing technique. adipic acid or A solution is prepared with sorbic acid or succinic acid or glutaric acid and xanthan gum. This The solution is sprayed onto the acid pellets by the fluidized bed pelletizing technique, thus making it very layered pellets are produced.
DEM ve dronedaron HCl pelletler ilk olarak silikon dioksit ile daha sonra da magnezyum stearat ile karistirilir. Son olarak pelletler, tabletler halinde basilir veya kapsüllerin içerisinde doldurulur. DEM and dronedarone HCl pellets were first mixed with silicon dioxide and then magnesium stearate. mixed with. Finally, the pellets are compressed into tablets or filled into capsules.
Bilesenler Miktar (%) Dronedaron HCI pelletler dronedaron HCl 5.00 - 98.00 mannitol 5.00 - 90.00 kroskarmelloz sodyum 5.00 - 40.00 karbomer 0.10 - 30.00 Enterik kaplama metakrilat kopolimeri Dabigatran eteksilat mesilat pelletler dabigatran eteksilat mesilat 1.00 - 85.00 seker pelleti 5.00 - 90.00 polivinilpirolidon (PVP) 0.10 - 30.00 kopolimeri (Eudragit EPO) veya PVA Inorganik asit pelletler nitrik asit '0.05 - 10.00 Mikrokristalize selüloz veya 5.0 ±- 40.00 mannitol veya Iaktoz silikon dioksit 0.1 - 0.20 kopolimeri (Eudragit EPO) veya PVA silikon dioksit 0.10 - 1.00 magnezyum stearat 0.10 - 3.00 Dronedaron HCI pelletlerin üretim prosesi: Dronedaron HCI, mannitol ve kroskarmelloz sodyum birarada karistirilir, sonrasinda karbomer solüsyonunun püskürtülmesiyle islak bir kütle olusturulur. Ekstrüzyon/sferonizasyon pelletleme teknigi ile bu islak kütleden pelletler üretilir. Components Quantity (%) Dronedarone HCl pellets dronedarone HCl 5.00 - 98.00 mannitol 5.00 - 90.00 croscarmellose sodium 5.00 - 40.00 carbomer 0.10 - 30.00 enteric coating methacrylate copolymer Dabigatran etexilate mesylate pellets dabigatran etexilate mesylate 1.00 - 85.00 sugar pellet 5.00 - 90.00 polyvinylpyrrolidone (PVP) 0.10 - 30.00 copolymer (Eudragit EPO) or PVA Inorganic acid pellets nitric acid '0.05 - 10.00 Microcrystalline cellulose or 5.0 ± 40.00 mannitol or lactose silicon dioxide 0.1 - 0.20 copolymer (Eudragit EPO) or PVA silicon dioxide 0.10 - 1.00 magnesium stearate 0.10 - 3.00 Production process of Dronedarone HCl pellets: Dronedarone HCl, mannitol and croscarmellose sodium is mixed together, then a wet mass is formed by spraying the carbomer solution. is created. Pellets are produced from this wet mass by the extrusion/spheronization pelletizing technique.
Enterik kaplama olarak metakrilik asit, metil metakrilatkopolimeri eklenerek bir solüsyon hazirlanir ve dronedaron HCl pelletler bu karisimin püskürtülmesi ile kaplanir. Methacrylic acid as enteric coating, adding methyl methacrylate copolymer to form a solution is prepared and dronedarone HCl pellets are coated by spraying this mixture.
Dabigatran pelletlerin üretim prosesi: DEM ve PVP eklenerek alkolik solüsyon/dispersiyon hazirlanir. Seker pelletler, bu solüsyon/dispersiyon ile kaplanir._ Etken madde ile kaplanan seker pelletler, önce metakrilik asit-etil akrilat kopolimeri (Eudragit EPO veya Polivinil alkol (PVA)) sonra da PVP solüsyonu ile kaplanir ve böylece DEM pelletler üretilmis olur. Production process of dabigatran pellets: Alcoholic solution/dispersion by adding DEM and PVP is prepared. Sugar pellets are coated with this solution/dispersion._ Sugar coated with active ingredient pellets, first methacrylic acid-ethyl acrylate copolymer (Eudragit EPO or Polyvinyl alcohol (PVA)) then coated with PVP solution and thus DEM pellets are produced.
Inorganik asit pelletlerin üretim prosesi: Mikrokristalize selüloz veya mannitol veya laktoz ve silikon dioksit harmanlanir, sonra seyreltilmis nitrik asit solüsyonu püskürtülerek yüksek parçalayicili granülatör veya akiskan yatak granülatör ile islak bir kütle olusturulur. Pelletler, akiskan yatakta metakrilik asit-etil akrilat kopolimer (Eudragit EPO) veya polivinil alkol (PVA) solüsyonu ile kaplanir, böylece inorganik asit pelletler üretilmis olur. Production process of inorganic acid pellets: Microcrystalline cellulose or mannitol or lactose and Silicon dioxide is blended, then diluted nitric acid solution is sprayed to high A wet mass is formed with a crusher granulator or a fluidized bed granulator. pellets, methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) in a fluidized bed covered with a solution of inorganic acid, thus producing inorganic acid pellets.
Dronedaron HCl pelletler ve Dabigatran eteksilat mesilat pelletler ve inorganik asit pelletleri karistirilir. Pelletler ilk önce silikon dioksit ile daha sonra da magnezyum stearat ile karistirilir. Dronedarone HCl pellets and Dabigatran etexilate mesylate pellets and inorganic acid pellets is mixed. The pellets are mixed first with silicon dioxide and then with magnesium stearate.
Pelletler son olarak tabletler halinde basilir veya kapsüller içerisine doldurulur. Pellets are finally pressed into tablets or filled into capsules.
Bilesenler Miktar (%) Dronedaron HCI pelletler dronedaron HCI 5.00 - 98.00 polivinilpirolidon (PVP) 0.10 - 30.00 seker pellet 5.00 - 90.00 Enterik kaplama polivinil asetat fitalat 0.10 - 30.00 Dabigatran eteksilat mesilat pelletler dabigatran eteksilat mesilat 1.00 - 85.00 adipik asit veya sorbik asit 5.00 - 95.00 veya süksinik asit veya glutarik asit metakrilik asit-Etil akrilat 0.05- 40.00 kopolimeri (Eudragit EPO) veya PVA mannitol 5.00 - 90.00 ksantan zamki 0.05 - 5.00 polivinil alkol (PVA) 0.05 - 20.00 silikon dioksit 0.10 - 1.00 magnezyum stearat 0.10 - 3.00 Çok katmanli pelletlerin üretim prosesi: Dronedaron ve PVP eklenerek bir solüsyon hazirlanir. Seker pelletler bu solüsyon/dispersiyonla kaplanir. dronedaron HCI ile kaplanan seker pelletler, polivinil asetat fitalat ile kaplanir ve böylelikle dronedaron HCl pelletler üretilmis olur. DEM ve mannitol, alkolik metakrilik asit-etil akrilat kopolimeri (Eudragit EPO) veya polivinil alkol (PVA) solüsyonu ile karistirilir. Bu karisim, dronedaron HCl pelletler üzerine püskürtülür. Components Quantity (%) Dronedarone HCl pellets dronedarone HCI 5.00 - 98.00 polyvinylpyrrolidone (PVP) 0.10 - 30.00 sugar pellets 5.00 - 90.00 enteric coating polyvinyl acetate phthalate 0.10 - 30.00 Dabigatran etexilate mesylate pellets dabigatran etexilate mesylate 1.00 - 85.00 adipic acid or sorbic acid 5.00 - 95.00 or succinic acid or glutaric acid methacrylic acid-Ethyl acrylate 0.05- 40.00 copolymer (Eudragit EPO) or PVA mannitol 5.00 - 90.00 xanthan gum 0.05 - 5.00 polyvinyl alcohol (PVA) 0.05 - 20.00 silicon dioxide 0.10 - 1.00 magnesium stearate 0.10 - 3.00 Production process of multi-layer pellets: Dronedarone and PVP are added to make a solution is prepared. Sugar pellets are coated with this solution/dispersion. coated with dronedarone HCI The sugar pellets were coated with polyvinyl acetate phthalate and thus dronedarone HCl pellets were produced. It is possible. DEM and mannitol, alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl mixed with an alcohol (PVA) solution. This mixture is sprayed onto dronedarone HCl pellets.
Adipik asit veya sorbik asit veya süksinik asit veya glutarik asit ve ksantan zamki eklenerek bir solüsyon hazirlanir. Bu solüsyonun pelletler pelletlerin üzerine püskürtülür ve böylelikle çok katmanli pelletler üretilmis olur. Çok katmanli pelletler, son olarak PVA ile kaplanir. Çok katmanli pelletler önce silikon dioksit ile, daha sonra da magnezyum stearat ile karistirilir. Pelletler tabletler halinde basilir veya kapsüller içerisine doldurulur. Adding adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum solution is prepared. The pellets of this solution are sprayed onto the pellets and thus very layered pellets are produced. Multilayer pellets are finally coated with PVA. The multilayer pellets are pre-mixed with silicon dioxide. and then mixed with magnesium stearate. Pellets are pressed into tablets or filled into capsules.
Bilesenler Miktar (%) Dronedaron HCI pelletler dronedaron HCI 5.00 - 98.00 polivinilpirolidon (PVP) 0.10 - 30.00 Seker pellet 5.00 - 90.00 Enterik kaplama metakrilik asit ko-polimeri tip 0.10 - 30.00 Dabigatran eteksilat mesilat pelletler dabigatran eteksilat mesilat 1.00 - 85.00 metakrilik asit-Etil akrilat 0.05 - 40.00 kopolimeri (Eudragit EPO) veya PVA mannitol 5.00 - 90.00 adipik asit veya sorbik asit 5.00 - 95.00 veya süksinik asit veya glutarik asit ksantan zamki 0.05 - 5.00 silikon dioksit 0.10 - 1.00 magnezyum stearat 0.10 - 3.00 Dronedaron HCI pelletlerin üretim prosesi: Dronedaron HCI ve PVP'nin eklenmesi ile bir solüsyon/dispersiyon hazirlanir. Seker pelletler bu solüsyon/dispersiyonla kaplanir. Etken madde ile kaplanan seker pelletler, metakrilik asit ko-polimeri tip C ile hazirlanir ve böylelikle Dronedaron HCI pelletler üretilmis olur. Components Quantity (%) Dronedarone HCl pellets dronedarone HCI 5.00 - 98.00 polyvinylpyrrolidone (PVP) 0.10 - 30.00 Sugar pellets 5.00 - 90.00 enteric coating methacrylic acid co-polymer type 0.10 - 30.00 Dabigatran etexilate mesylate pellets dabigatran etexilate mesylate 1.00 - 85.00 methacrylic acid-Ethyl acrylate 0.05 - 40.00 copolymer (Eudragit EPO) or PVA mannitol 5.00 - 90.00 adipic acid or sorbic acid 5.00 - 95.00 or succinic acid or glutaric acid xanthan gum 0.05 - 5.00 silicon dioxide 0.10 - 1.00 magnesium stearate 0.10 - 3.00 Production process of Dronedarone HCl pellets: With the addition of Dronedarone HCl and PVP, a the solution/dispersion is prepared. Sugar pellets are coated with this solution/dispersion. Active The sugar pellets coated with the substance are prepared with the methacrylic acid co-polymer type C and thus Dronedarone HCl pellets are produced.
Dabigatran pelletlerin üretim prosesi: DEM ve mannitol monohidrat birarada karistirilir. Bu karisimin üzerine alkolik metakrilik asit-etil akrilat kopolimeri (Eudragit EPO) veya polivinil alkol (PVA) solüsyonu püskürtülür ve akiskan yatakli pelletleme teknigi ile pelletler üretilir. Adipik asit veya sorbik asit veya süksinik asit veya glutarik asit ve ksantan zamki eklenerek bir solüsyon hazirlanir. Bu solüsyon, akiskan yatakli pelletleme teknigi ile DEM pelletler üzerine püskürtülür ve böylelikle çok katmanli pelletler üretilmis olur. Production process of dabigatran pellets: DEM and mannitol monohydrate are mixed together. This alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol on the mixture (PVA) solution is sprayed and pellets are produced by fluidized bed pelletizing technique. adipic acid or a solution by adding sorbic acid or succinic acid or glutaric acid and xanthan gum is prepared. This solution is sprayed onto DEM pellets by fluidized bed pelletizing technique. and thus multi-layered pellets are produced.
Dabigatran eteksilat mesilat ve dronedaron HCl pelletler ilk olarak silikon dioksit ile daha sonra da magnezyum stearat ile karistirilir. Son olarak pelletler, özel tablet baski makinesi ile üretilen çok katmanli döner tablet basim makinesi ile sikistirilir veya özel tablet baski makinesi ile çekirdek üzerinde dronedaron HCI pelletlere sahip kuru tablet içinde tablet veya inlay tabletler üretilmektedir. Dabigatran etexilate mesylate and dronedarone HCl pellets were first mixed with silicon dioxide and then mixed with magnesium stearate. Finally, the pellets are produced with a special tablet press machine. Compressed with multilayer rotary tablet press machine or with special tablet press machine dry tablet-in-tablet or inlay tablets with dronedarone HCl pellets on the core is produced.
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2015/02223A TR201502223A2 (en) | 2015-02-25 | 2015-02-25 | Pharmaceutical combinations of dronedarone and dabigatran |
PCT/EP2016/053819 WO2016135171A1 (en) | 2015-02-25 | 2016-02-24 | Pharmaceutical combinations of dronedarone and dabigatran |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2015/02223A TR201502223A2 (en) | 2015-02-25 | 2015-02-25 | Pharmaceutical combinations of dronedarone and dabigatran |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201502223A2 true TR201502223A2 (en) | 2016-09-21 |
Family
ID=53502822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2015/02223A TR201502223A2 (en) | 2015-02-25 | 2015-02-25 | Pharmaceutical combinations of dronedarone and dabigatran |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201502223A2 (en) |
WO (1) | WO2016135171A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665444B1 (en) | 1990-08-06 | 1992-11-27 | Sanofi Sa | AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM. |
PE121699A1 (en) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN |
FR2764800B1 (en) | 1997-06-23 | 1999-09-10 | Sanofi Sa | SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN DERIVATIVES |
PT1870100E (en) | 2002-03-07 | 2012-04-17 | Boehringer Ingelheim Int | Ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1h-benzimidazole-5-carbonyl)-2-pyridylamino)propionate methansulfonate |
US20110136779A1 (en) * | 2009-11-23 | 2011-06-09 | Milner Peter G | Methods for stroke reduction in atrial fibrillation patients |
WO2012023024A2 (en) * | 2010-08-17 | 2012-02-23 | Lupin Limited | Controlled release formulations of dronedarone |
-
2015
- 2015-02-25 TR TR2015/02223A patent/TR201502223A2/en unknown
-
2016
- 2016-02-24 WO PCT/EP2016/053819 patent/WO2016135171A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016135171A1 (en) | 2016-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8715730B2 (en) | Therapeutic or prophylactic agent for dyskinesia | |
CA2606740A1 (en) | Quinine-containing controlled-release formulations | |
JP2019069981A (en) | Pharmaceutical composition containing irbesartan and amlodipine or salt thereof | |
JP2010248106A (en) | Film-coated tablet | |
MX2013013571A (en) | Pharmaceutical composition of rosuvastatin calcium. | |
US11510878B2 (en) | Extended release multiparticulates of ranolazine | |
JPWO2015122477A1 (en) | Film-coated orally disintegrating tablets | |
EP2722033A1 (en) | Pharmaceutical Compositions of Dabigatran Free Base | |
EP3103444A1 (en) | Pharmaceutical compositions of lacosamide and eslicarbazepine | |
WO2015169957A1 (en) | Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists | |
JPH11147819A (en) | Stabilized medicinal preparation | |
JP5818219B2 (en) | Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative | |
US10172842B2 (en) | Sustained release oral dosage form containing dalfampridine | |
WO2016131896A1 (en) | Pharmaceutical combinations of dronedarone and rivaroxaban | |
WO2023067620A1 (en) | Orally disintegrating pharmaceutical compositions of rivaroxaban | |
EP3342401A1 (en) | Bilayer tablet formulations of dabigatran etexilate | |
TR201502223A2 (en) | Pharmaceutical combinations of dronedarone and dabigatran | |
WO2017013106A1 (en) | Pharmaceutical formulations of dabigatran free base | |
ES2643287T3 (en) | Lacosamide oral disintegration formulations | |
WO2017134200A1 (en) | A novel pharmaceutical composition of vorapaxar and metoprolol | |
RU2744270C2 (en) | Compressed pharmaceutical product | |
WO2017198783A1 (en) | New oral pharmaceutical formulations of dabigatran | |
WO2019203748A2 (en) | The composition comprising raloxifene with at least one antipsychotic agent | |
WO2014027974A1 (en) | Orally disintegrating formulation of paliperidone | |
TR2021021538A2 (en) | A PHARMACEUTICAL COMBINATION CONTAINING IBUPROFEN AND AT LEAST ONE ATYPICAL ANTIPSYCHOTIC AGENT |